B lymphocytes and systemic lupus erythematosus
Rent the article at a discountRent now
* Final gross prices may vary according to local VAT.Get Access
Systemic lupus erythematosus (SLE) is a prototypic autoim-mune disease characterized by B cell hyperactivity in associa-tion with autoantibodies, most prominently those directed to components of the cell nucleus. The source of the antigens that drive B cell responses in SLE is unknown, although recent studies suggest mechanisms by which the self-antigens become immunogenic and stimulate responses. Among these mecha-nisms, abnormalities in the generation of apoptotic cells or their clearance may increase the availability of nuclear antigens to drive responses. In addition, autoantibody crossreactivity may promote induction of responses to disparate antigens, foreign and self, and enable a single autoantibody to cause dis-ease by crossreactive binding. In addition to reflecting increased exposure to self-antigen, autoantibody responses in SLE may result from abnormalities in B cell signaling and regu-lation by cytokines. New approaches to therapy aim to abro-gate autoantibody production by targeting specific steps in B cell activation, including blockade of T cell costimulation.
- Cocca BA, Cline AM, Radic MZ: Blebs and apoptotic bodies are B cell autoantigens. J Immunol 2002, 169:159–166.
- Mitchell DA, Pickering MC, Warren J, et al.: C1q deficiency and autoimmunity: the effects of genetic background on disease expression. J Immunol 2002, 168:2538–2543.
- Cohen PL, Caricchio R, Abraham V, et al.: Delayed apoptotic cell clearance and lupus-like autoimmunity in mice lacking the c-mer membrane tyrosine kinase. J Exp Med 2002, 196:135–140. This study provides compelling data on the relationship between apo-ptotic cell clearance and development of autoimmunity. CrossRef
- Lu Q, Lemke G: Homeostatic regulation of the immune sys-tem by receptor tyrosine kinases of the Tyro 3 family. Science 2001, 293:306–311. CrossRef
- Boes M, Schmidt T, Linkemann K, et al.: Accelerated develop-ment of IgG autoantibodies and autoimmune disease in the absence of secreted IgM. PNAS 2000, 97:1184–1189. CrossRef
- Ehrenstein MR, Cook HT, Neuberger MS: Deficiency in serum immunoglobulin M predisposes to development of IgG autoantibodies. J Exp Med 2000, 191:1253–1257. CrossRef
- Kim SJ, Gershov D, Ma X, et al.: I-PLA2 activation during apop-tosis promotes the exposure of membrane lysophosphatidyl-choline leading to binding by natural immunoglobulin M antibodies and complement activation. J Exp Med 2002, 196:655–665. This study indicates that IgM, but not IgG, antibodies bind to apoptotic cells and promote complement binding. As such, IgM may promote the uptake of apoptotic cells and modify their properties in inflammation. CrossRef
- Baumann I, Kolowos W, Voll RE, et al.: Impaired uptake of apoptotic cells into tingible body macrophages in germinal centers of patients with systemic lupus erythematosus. Arthri-tis Rheum 2002, 46:191–201. Increased numbers of apoptotic cells were identified in lymph nodes from patients with SLE and lymphadenopathy, suggesting that increased production of apoptotic cells or decreased clearance may be an element of the pathogenesis of SLE. CrossRef
- Scaffidi P, Misteli T, Blanchi ME: Release of chromatin protein HMGB1 by necrotic cells triggers inflammation. Nature 2002, 418:191–195. CrossRef
- Tran HB, Ohlsson M, Beroukas D, et al.: Subcellular redistribu-tion of La/SSB autoantigen during physiologic apoptosis of the fetal mouse heart and conduction system. Arthritis Rheum 2002, 46:202–208. CrossRef
- Tran HB, Macardle PJ, Hiscock J, et al.: Anti-La/SSB antibodies transported across the placenta bind apoptotic cells in fetal organs targeted in neonatal lupus. Arthritis Rheum 2002, 46:1572–1579. This study demonstrates that La, a protein normally sequestered within cells, becomes available for antibody binding during apopto-sis. This finding shows a mechanism for direct pathogenicity of maternal anti-La antibodies in fetal heart block. CrossRef
- Sharma A, Isenberg DA, Diamond B: Crossreactivity of human anti-dsDNA antibodies to phosphorylcholine: clues to their origin. J Autoimmunity 2001, 16:479–484. CrossRef
- Putterman C, Diamond B: Immunization with a peptide surro-gate for dsDNA induces autoantibody production and renal immunoglobulin deposition. J Exp Med 1998, 188:29–38. CrossRef
- DeGiorgio LA, Konstantinov KN, Lee SC, et al.: A subset of lupus anti-DNA antibodies cross-reacts with the NR2 glutamate receptor in systemic lupus erythematosus. Nat Med 2001, 7:1189–1193. This study suggests a novel mechanism by which anti-DNA antibodies can mediate central nervous system lupus, with crossreactive binding with the NR2 receptor leading to neuronal death in a mouse model. CrossRef
- Mostoslavsky G, Fischel R, Yachimovich N, et al.: Lupus anti-DNA autoantibodies cross-react with a glomerular structural protein: a case for tissue injury by molecular mimicry. Eur J Immunol 2001, 31:1221–1227. CrossRef
- Ho A, Madger LS, Barr SG, Petri M: Decreases in anti-dsDNA lev-els are associated with concurrent flares in patients with sys-temic lupus erythematosus. Arthritis Rheum 2001, 44:2342–2349. CrossRef
- Arbuckle MR, James JA, Kohlhase KF, et al.: Development of anti-dsDNA autoantibodies prior to clinical diagnosis of systemic lupus erythematosus. Scand J Immunol 2001, 54:211–219. Using a unique resource from the military, this study demonstrates that anti-double-strand DNA antibodies are detectable in many patients years before the diagnosis of SLE. This finding suggests that pathogenic events in SLE may occur years before clinical disease onset, pointing to a role for screening in the future when disease mechanisms are better understood. CrossRef
- Robinson WH, DiGennaro C, Hueber W, et al.: Autoantigen microarrays for multiplex characterization of autoantibody responses. Nat Med 2002, 8:295–301. Transfer of microarray technology into the realm of autoantibodies has implications for discovering protein targets of these autoantibod-ies to define disease better and develop targeted therapies. CrossRef
- Pisetsky DS: Antibody responses to DNA in normal immunity and aberrant immunity. Clin Diag Lab Immunol 1998, 5:1–6.
- Pisetsky DS, Wenk KS, Reich CF: The role of CpG sequences in the induction of anti-DNA antibodies. Clin Immunol 2001, 100:157–163. CrossRef
- Vallin H, Perers A, Alm GV, Ronnblom L: Anti-double stranded DNA antibodies and immunostimulatory plasmid DNA in combination mimic the endogenous IFN-a inducer in sys-temic lupus erythematosus. J Immunol 1999, 163:6306–6313.
- Ledbetter EA, Rifkin IR, Hohlbaum AM, et al.: Chromatin-IgG complexes activate B cells by dual engagement of IgM and Toll-like receptors. Nature 2002, 416:603–607. A very novel observation to explain how chromatin can drive ANA responses. Because this system involves a rheumatoid factor trans-genic mouse, the relationship to events in SLE is not clear. CrossRef
- Vidaver R: Molecular and clinical evidence of the role of estrogen in lupus. Trends I mmunol 2002, 23:229–230. An excellent review of recent findings of mechanisms by which estrogen can contribute to the development and maintenance of autoimmunity. CrossRef
- Mor G, Munoz A, Redlinger R, et al.: The role of the fas/fas-ligand system in the estrogen-induced thymic alteration. Am J Reprod Immunol 2001, 46:4298–4307. CrossRef
- Grimaldi CM, Michael DJ, Diamond B: Expansion and activa-tion of a population of autoreactive marginal zone B cells in a model of estrogen-induced lupus. J Immunol 2001, 167:1886–1890.
- Mackay F, Browning JL: BAFF: a fundamental survival factor for B cells. Nat Rev 2002, 2:465–475. A comprehensive review of the effects of BAFF on B cell survival and acti-vation, with implications for interventions to decrease autoimmunity. CrossRef
- Khare SD, Hsu H: The role of TALL-1 and APRIL in immune regulation. Trends Immunol 2001, 22:61–63. CrossRef
- Khare SD, Sarosi I, Xia XZ, et al.: Severe B cell hyperplasia and autoimmune disease in TALL-1 transgenic mice. PNAS 2000, 97:3370–3375. CrossRef
- Cheema GS, Roschke V, Hilbert DM, Stohl W: Elevated serum B lymphocyte stimulator levels in patients with systemic immune-based rheumatic diseases. Arthritis Rheum 2001, 44:1313–1319. This study shows that patients with autoimmune diseases have ele-vated serum BAFF levels, providing a basis for anti-BAFF therapies in treating SLE and other autoimmune diseases. CrossRef
- Zhang J, Roschke V, Baker KP, et al.: A role for B lymphocyte stimulator in systemic lupus erythematosus. J Immunol 2001, 166:6–10.
- Morel L, Blenman KR, Croker BP, Wakeland EK: The major murine systemic lupus erythematosus susceptibility locus, Sle1, is a cluster of functionally related genes. PNAS 2001, 98:1787–1792. CrossRef
- Sobel ES, Satoh M, Chen Y, et al.: The major murine systemic lupus erythematosus susceptibility locus, Sle1 results in abnormal functions of both B and T cells. J Immunol 2002, 169:2694–2700.
- Mohan C, Liu F, Xie C, Williams RC: Anti-subnucleosome reac-tivities in systemic lupus erythematosus patients and their first degree relatives. Clin Exp Immunol 2001, 123:119–126. CrossRef
- Yin Z, Bahtiyar G, Zhang Na, et al.: Il-10 regulates murine lupus. J Immunol 2002, 169:2148–2155.
- Llorente L, Richaud-Patin Y, Garcia-Padilla C, et al.: Clinical and biologic effects of anti-interleukin 10 monoclonal anti-body administration in systemic lupus erythematosus. Arthri-tis Rheum 2000, 43:1790–1800. CrossRef
- Davis JC, Totoritis MC, Rosenberg J, et al.: Phase I clinical trial of a monoclonal antibody against CD40-Ligand (IDEC-131) in patients with systemic lupus erythematosus. J Rheumatol 2001, 28:95–101.
- Kalunian KC, Davis JC, Merrill JT, et al.: Treatment of systemic lupus erythematosus by inhibition of T cell costimulation with anti-CD154. Arthritis Rheum 2002, 46:3251–3258. This well-designed and controlled study failed to show efficacy of anti-CD40L therapy for SLE. The antibody treatment, however, was well tolerated. CrossRef
- Boumpas DT, Furie RA, Manzi S, et al.: A short course of BG9588 (anti-CD40L antibody) improves serologic activity and decreases hematuria in patients with proliferative lupus glomerulonephritis. Arthritis Rheum 2001, 44S:S387.
- Huang W, Sinha J, Newman J, et al.: The effect of anti-CD40 Ligand antibody on B cells in human systemic lupus erythe-matosus. Arthritis Rheum 2002, 46:1554–1562. CrossRef
- Perrotta S, Locatelli F, LaManna A, et al.: Anti-CD20 mono-clonal antibody for life-threatening autoimmune hemolytic anemia in a patient with systemic lupus erythematosus. B J Hematol 2002, 116:465–467.
- Strand V: Monoclonal antibodies and other biologic thera-pies. Lupus 2001, 10:216–221. A comprehensive review of the use of targeted monoclonal antibodies to treat SLE. The article discusses targets such as cytokines and mole-cules mediating costimulation. CrossRef
- Spertini F, Leimgruber A, Morel B, et al.: Idiotypic vaccination with a murine anti-dsDNA antibody: phase I study in patients with nonactive systemic lupus erythematosus with nephritis. J Rheum 1999, 26:2602–2608.
- Lindorfer MA, Schuman TA, Craig ML, et al.: A bispecific dsDNA X monoclonal antibody construct for clearance of anti-dsDNA IgG in systemic lupus erythematosus. J Immunol Methods 2001, 248:125–138. CrossRef
- Daikh DI, Wofsy D: Effects of anti-B7 monoclonal antibodies on humoral immune responses. J Autoimmunity 1999, 12:101–108. CrossRef
- Girschick HJ, Grammer AC, Nanki T, et al.: Expression of recombination activating genes 1 and 2 in peripheral B cells of patients with systemic lupus erythematosus. Arthritis Rheum 2002, 46:1255–1263. CrossRef
- B lymphocytes and systemic lupus erythematosus
Current Rheumatology Reports
Volume 5, Issue 4 , pp 264-269
- Cover Date
- Print ISSN
- Online ISSN
- Current Medicine Group
- Additional Links